Classify an EU variation, check eCTD v4.0 readiness, and see what the 2023–2028 Pharma Reform means for your product — in under five minutes.
Built against the actual text of the January 2026 EU Variations Guideline (Commission Notice C/2025/5045), the consolidated Variations Regulation (EC) No 1234/2008, and the current EU Pharma Reform legislative file — not a generic summary.
This is draft decision-support, not a regulatory submission or legal opinion. It does not have complete Annex II sub-code coverage and cannot replace a full classification review. Verify every result against the current EMA/national guideline before acting on it — and see the reasoning trail under each result so you can check the logic yourself, not just the answer.
Describe the change(s)
Plain language is fine — describe it the way you'd say it out loud, not as a legal category. Add one row per distinct change if you're planning to submit several together; each gets its own classification, and you'll get one recommended overall submission approach at the end.
Used only to flag which ruleset applies — nothing is stored.
Reasoning grounded in Commission Notice C/2025/5045 (applicable from 15 Jan 2026) and Regulation (EC) No 1234/2008 as consolidated to 01/01/2025. Sourced and cross-checked 2026-08-22 — see WRPA's own regulatory-affairs knowledge base for full citations. Keyword matching is intentionally broad to handle plain-language descriptions — always sanity-check an unexpected result rather than trusting it blindly. The "Concerned CTD part(s)" and "Timeline by phase" blocks under each result use the same keyword-matching approach and the ICH M4 module structure — treat them as a starting checklist, not a formal dossier-impact assessment, and note where a phase's duration is explicitly stated as unconfirmed in the source text rather than guessed.
eCTD v4.0 readiness check
v4.0 is built on HL7 RPS — a single unified XML message with context-group/keyword/priority metadata, replacing v3.2.2's per-sequence backbone messages. For good content, a v4.0 dossier looks similar to v3.2.2; the real learning curve is the new metadata concepts and validated tooling, not the underlying science. Note: "EMA" below means the centralised procedure specifically — if you file via MRP/DCP/national routes, that's a separate, later-moving track (see below), not covered by EMA's own centralised-procedure timeline.
Adoption dates verified against EMA's own published timeline and cross-checked against detailed third-party technical reports (IntuitionLabs; Perceptive; Freyr Solutions) where ICH's/EMA's own sites could not be fetched directly. The EU NCA (MRP/DCP/national) track specifically is reported as separate and less mature than EMA's centralised-procedure track — treat its dates as more provisional than the FDA/EMA/PMDA figures above. Re-check ich.org / your target regulator's site before finalising a project timeline — these dates move.
What the 2023–2028 EU Pharma Reform means for a decision you're actually making
If you're an RA professional, you already know whether your product is orphan-designated or an ATMP — that's not the useful question. The useful question is what a known characteristic means under rules that are still being finalised, and what's genuinely still open versus settled enough to act on. This tab assumes you know your product; it's built to translate, not to diagnose.
This changes which of the open items below actually matter to you — a renewal decision and a licensing valuation care about different unresolved questions.
Based on WRPA's tracked reading of the reform file (procedures 2023/0131(COD) and 2023/0132(COD) on the official EU Law Tracker) as of 2026-08-22. Several figures below (180/150-day CHMP timelines, unlimited MA validity, ERA scope) rest on secondary legal commentary, not yet the adopted text — flagged inline.
Want this checked properly, not just flagged?
This tool is a starting point, not a submission-ready answer. WRPA offers a fixed-scope EU Pharma Reform / eCTD v4.0 / Variation readiness diagnosis — a short, bounded engagement with a concrete gap list and priority plan at the end.